You are here

SARC019

Completed
A randomized, phase 3 study of dose escalation versus no dose escalation of Imatinib in metastatic GIST patients with Imatinib trough levels less than 1100 nanograms/mL
Type of Sarcoma: 
Metastatic GIST
Drug: 
Imatinib
Accrual Status: 
Closed
Overall Study Principal Investigator: 

Suzanne George, MD
Dana-Farber Cancer Institute

For more information about this trial and open sites: